Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24717680 | 0.86 | CRBN (0.51) | CRBNIKZF2CSNK1A1DDB1 | |
| SCHEMBL21477242 | 0.83 | CRBN (0.65) | CRBNDDB1 | |
| SCHEMBL20231758 | 0.82 | ESR1 (0.48) | CRBNESR1DDB1 | |
| SCHEMBL24717677 | 0.82 | CRBN (0.54) | CRBNIKZF2DDB1 | |
| SCHEMBL26184312 | 0.82 | CRBN (0.56) | CRBNIKZF2DDB1 | |
| SCHEMBL30270743 | 0.82 | CRBN (0.56) | CRBNIKZF2CSNK1A1DDB1 | |
| SCHEMBL25012254 | 0.82 | CRBN (0.56) | CRBNIKZF2CSNK1A1DDB1 | |
| SCHEMBL25010116 | 0.80 | CRBN (0.54) | CRBNIKZF2DDB1 | |
| SCHEMBL25010168 | 0.80 | CRBN (0.54) | CRBNIKZF2DDB1 | |
| SCHEMBL25010291 | 0.79 | CRBN (0.51) | CRBNIKZF2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| CN-118574821-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |